Literature DB >> 14508386

The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity.

Carl M J Kirkpatrick1, Stephen B Duffull, Evan J Begg, Chris Frampton.   

Abstract

A retrospective review was undertaken in 744 patients who were dose-individualized with gentamicin once daily to evaluate a change in gentamicin clearance as a potential predictor of nephrotoxicity. The definition of nephrotoxicity was chosen to be a change in creatinine clearance greater than 20%. Similarly, a change in gentamicin clearance of greater than 20% was also considered a possible index of nephrotoxicity. Four criteria were developed to assess the usefulness of gentamicin clearance as a predictor of nephrotoxicity. Following the application of the inclusion/exclusion criteria, 132 patients were available for the analysis. The sensitivity, specificity, positive predictive value, and negative predictive value were assessed for each of the criteria. Receiver operating characteristic (ROC) curves were produced to determine if an optimum value in the change of gentamicin clearance could be found to maximize sensitivity and specificity. The overall incidence of nephrotoxicity based on a decrease in creatinine clearance by 20% or more was 3.8%. Women were overrepresented in the nephrotoxic group [71.4% versus 40.1% (P = 0.0025)]. Patients with nephrotoxicity had statistically longer treatment periods, increased cumulative dose, and more dosing predictions (P < 0.05 in each case). The sensitivity of the criteria ranged from 43 to 46%, and specificity ranged from 93 to 99%. The positive and negative predictive values ranged from 63 to 94% and 86 to 89%, respectively. In those patients in whom nephrotoxicity was predicted from a change in gentamicin clearance, this change occurred on average 3 days before the change in creatinine clearance (P < 0.05). A change in gentamicin clearance to predict nephrotoxicity may be a useful addition to current monitoring methods, although it is not the complete answer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508386     DOI: 10.1097/00007691-200310000-00012

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Authors:  Christine E Staatz; Colette Byrne; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

2.  Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.

Authors:  Iona Macdonald; Christine E Staatz; Roger W Jelliffe; Alison H Thomson
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

3.  Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Yusuke Tanigawara; Reiko Sato; Kunihiko Morita; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

Review 4.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration.

Authors:  Claire Johnston; Sarah N Hilmer; Andrew J McLachlan; Slade T Matthews; Peter R Carroll; Carl M Kirkpatrick
Journal:  Eur J Clin Pharmacol       Date:  2014-02-14       Impact factor: 2.953

Review 6.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.